Kornimate/medical-research-clean huggingface dataset:
child of urban poverty iron project (cupip) - a pilot study

Conditions: Iron-deficiency; Iron Deficiency Anemia; Micronutrient Deficiency; Nutrient Deficiency; Stunting

Summary: the first 1,000 days of life are critical periods for brain development. proper nutrition lays the foundation for optimal growth, health, and neurodevelopment across the lifespan. poor nutrition in this vulnerable period has irreversible consequences, including stunting, susceptibility to sickness, reduced school performance and productivity, and impaired intellectual and social development. unicef reported in 2018 that among the low cost flat residents in urban areas of the klang valley, 15% of children under 5 years old were stunted, 22% underweight, and 23% either overweight or obese. will a micronutrient supplementation program improve the growth and iron status of children aged 6 months to 5 years staying in lembah subang? children will be randomized into treatment and control groups. treatment groups will receive dietary micronutrient supplementation packets. measurements of height and weight and iron status will be taken at baseline and 4 months later.

this is a pilot study in a single-centre, using a single-blind, two-parallel group, randomized trial conducted amongst children aged 6 months to 5 years residing at ppr lembah subang, located in the state of selangor, malaysia between october 2019 and february 2020 (4 months). the participants were randomly assigned in a 3:2 treatment-to-control allocation to receive, in addition to the baseline deworming treatment, either daily micronutrient packets for 4 months (intervention arm) or no micronutrient supplementation (control group). this residency area comprises a local population with mixed ethnic makeup and poor socioeconomic status (majority are b40). we distributed flyers, posters, and leaflets with the help of the community mothers in ppr communities to encourage participation. registration, informed consent and anthropometric measurements, dietary logs and blood drawn for iron status were taken prior to randomization. all children received a baseline deworming treatment at this point. the treatment group received baseline deworming medications, a 4-month supply of daily micronutrient supplementation and a compliance monitoring log. the control group only received similar baseline deworming medications without any daily micronutrient supplementation. only the research investigators and outcome assessors were masked to the treatment status whilst the participants and interventionists research investigators were aware of the assigned intervention. primary endpoints assessed in this study are changes in serum ferritin and hemoglobin levels at 0 and 4 months after interventions. the secondary endpoints are changes in age-and-sex standardized height and weight percentile scores at 0 and 4 months after micronutrient supplementation.

Eligibility criteria:
inclusion criteria: * children aged 6 months to 5 years living in ppr lembah subang exclusion criteria: * ex-premature babies and children with congenital abnormalities resulting in gross impairment * children whose caregiver did not consent to participation
buprenorphine detoxification with two types of treatment. bbd iii - 12

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone.


Eligibility criteria:
please contact site for information.
running slopes and power performance

Conditions: Healthy

Summary: the objective of the present study was to determine the effect of interval session running at high intensity with 1% or 10% gradient on the height of the drop jump. the cinematic variables concentric phase, eccentric and contact time were compared after the running session in both conditions in order to explain possible changes in the jump performance. the investigators theorize that the lower eccentric overload in the running to 10% inclination promotes higher deleterious effect on power performance of the lower limbs

physical training programs are typically composed of activities directed to the development of different valences usually stimulated in the same session. when aerobic activities of long duration prior isokinetic strength exercises, isotonic, or explosive, deleterious effects seem to be induced on performance of these valences. these short and long-term changes in muscle strength and power would be directly associated with repetitive eccentric loads that characterize the endurance running. gradual increases in the running slope were inversely associated with a proportional reduction in the eccentric loads, which in turn would result in less muscle damage to intra and extrafusal fibers. so, the change in the slope of the race would emerge as an optional way to neutralize the competitive effect on the power performance. the research consisted of five visits. at the initial visit was conducted familiarization to vertical drop jump, and immediately after, the determination of vo2max values and their associated speed (vvo2max). the second visit was a new familiarization for the vertical drop jump followed immediately determining the time to exhaustion performance in vvo2max (100% of vo2max). two jumps were performed on each of the three selected heights (20, 30 and 40 cm) were used in the experimental sessions and control only the height associated with the highest performance. in subsequent visits (third to fifth), participants performed three maximum jumps before and about 10 min after the following conditions: high intensity interval running a 10% gradient (c10%), 1% grade (c1%) and control condition (con).

Eligibility criteria:
inclusion criteria: * age: 18 at 45 years * no cardiovascular or metabolic problems * minimum level of aerobic activity recommended by american college of sports medicine exclusion criteria: * no joint or muscle injuries * no use ergogenic or anabolic resources

Keywords: drop jump high intensity interval training muscle fatigue aerobic performance
diesel exhaust inhalation, systemic nitric oxide inhibition and cardiac output

Conditions: Vascular Function in Healthy Volunteers

Summary: exposure to combustion-derived fine particulate air pollution is associated with cardiovascular mortality and morbidity. in previous studies, exposure to diesel exhaust (a major constituent of urban particulate air pollution) has been shown to impair two important functions of the vascular endothelium: vascular vasomotor function and endogenous fibrinolysis. our subsequent studies suggest this impairment of vascular function is mediated by a reduction in nitric oxide bioavailability. in this study we aim to investigate the cardiovascular responses to systemic nitric oxide synthase inhibition following exposure to dilute diesel exhaust.


Eligibility criteria:
inclusion criteria: * healthy volunteers * non smokers * no regular medication (except oral contraceptive) * no recent respiratory tract infection (within 6 weeks) exclusion criteria: * history of asthma or respiratory disease * smoking history * pregnancy (positive urinary pregnancy test)

Keywords: nitric oxide diesel exhaust air pollution cardiac output healthy volunteers
explorative study of azd1305 in atrial fibrillation patients

Conditions: Atrial Fibrillation

Summary: explorative study in atrial fibrillation patients to assess safety and pharmacokinetics at initiation of treatment and at steady state


Eligibility criteria:
inclusion criteria: * documented atrial fibrillation but in stable sr for at least 2 h and a maximum of 28 days. * sinus rhythm at randomisation exclusion criteria: * haemodynamically unstable condition as judged by the investigator, systolic bp \ 180 mmhg, or diastolic bp \>105 mmhg at randomisation * personal or family history of torsades de pointes (tdp), any other polymorphic ventricular tachycardia (pvt), sustained ventricular tachycardia, long qt syndrome and/or brugada syndrome * sinus bradycardia (\<50 beats per minute (bpm)) at randomisation * qtc (fridericia, qtcf ) \>450 ms measured in sinus rhythm at randomisation, * serum potassium below 3.8 or above 5.0 mmol/l or plasma potassium below 3.6 or above 5.0 mmol/l * qrs duration \>120 ms at randomisation * use of any antiarrhythmic drug class i and/or iii, digitalis glycoside, qt prolonging drug and/or drug that inhibits cyp3a4, as well as st john's worth
a component analysis of acceptance and commitment therapy

Conditions: Long-term Physical Health Conditions; Mild to Moderate Anxiety and/or Depression

Summary: the purpose of this study is to determine whether a specific component of acceptance and commitment therapy (act) called 'self as context' is an important and necessary part of this therapeutic approach.


Eligibility criteria:
inclusion criteria: * adults of working age (18-65) * patients with a primary positive diagnosis of a long-term health condition (the most common conditions referred to the service are diabetes, chronic obstructive pulmonary disease \[copd\], rheumatoid arthritis and epilepsy) where there is a verifiable medical diagnosis supported by the patients general practitioner (gp) and/or secondary care physician * patients with concurrent mental health difficulties (defined as mild - moderate anxiety and/or depression, see table one). exclusion criteria: * patients with a primary diagnosis of 'medically unexplained symptoms' (mus) including somatoform disorders (e.g. pain disorder, conversion disorder, body dysmorphic disorder, hypochondriasis) and functional somatic syndromes (e.g. irritable bowel syndrome, chronic fatigue syndrome, fibromyalgia, non-cardiac chest pain, non-epileptic seizures) * mental health diagnoses in addition to mild - moderate anxiety / depression (e.g. personality disorder, bipolar disorder, psychosis etc.) * patients in receipt of secondary care mental health services * patients with severe and enduring mental health difficulties * significant risk issues, or current substance misuse * previous contact with mental health services (defined as two or more prior episodes of contact without significant change) * inpatient admission for mental health difficulties within the last five years * history of overdoses or other self-injury * stated reluctance to engage in psychotherapy
trial to determine the immunomodulatory activity of ptm-001 in patients with hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: study ptm-001-01 is a 12-week, randomized, placebo controlled, double blind study with a 12 week open-label extension to examine the immunomodulatory activity of ptm-001 in participants with hidradenitis suppurativa (hs). participants will be randomized to receive ptm-001 (400 mg) or matching placebo every day for 12 weeks after which all participants will receive open-label ptm-001 400 mg daily for an additional 12 weeks. randomization will be stratified by hurley stage.


Eligibility criteria:
inclusion criteria: * had onset of symptoms consistent with hs at least 6 months prior to screening. * has had active hs for at least 2 months. * has ≥ 5 hs abscesses or inflammatory nodules at screening. * agrees to maintain baseline wound care and antibiotic therapy, including oral antibiotics, for the duration of the trial. * agrees to use contraception exclusion criteria: * has other skin disease or condition that can interfere with hs assessment. * has a positive test for tb, hiv, hepatitis b and/or hepatitis c at screening. * has a history of retinopathy or known clinically significant cardiovascular or hematologic conditions. * has taken any biologic drug within 3 serum half-lives. a list of potential biologics and their half-lives * has started oral antibiotics within 28 days of study day 1. * has, within 2 weeks prior to day 1, received a medication prohibited based on cytochrome p450 (cyp3a4) interaction * has such extensive disease that, in the opinion of the investigator, it is difficult to discriminate between active lesions and scarring. * has more than 15 active tunnels at screening. * is pregnant, nursing or considering becoming pregnant. * has a history of malignancy except non-melanoma skin cancer or cervical carcinoma in situ.

Keywords: hidradenitis suppurativa hs inflammatory skin disease humira p2x7 il-1β
open trial of technology-enhanced behavioral intervention for buprenorphine retention in pregnant and postpartum people

Conditions: Opioid Use Disorder; Pregnancy Related

Summary: this study involves testing how useful a technology-enhanced intervention is for pregnant people prescribed buprenorphine for the management of opioid use disorder. the intervention being studied is a brief therapy protocol and a mobile application. participation involves four 60-minute therapy appointments during pregnancy, and four 30-minute therapy appointments at the end of pregnancy through 3 months postpartum. the mobile application will be accessible for at least the duration of the study. participants will also be asked to complete questionnaires at enrollment and again at 1-month postpartum and 3-months postpartum, will send monthly photos of their prescription bottle/box, and will be contacted randomly throughout the study to perform a medication count. the total duration of the study is between 5-9 months depending on when you enroll (early second trimester-mid third trimester). compensation is provided.

medication for opioid use disorder (moud) can effectively prevent overdose and death for pregnant and postpartum people with opioid use disorder (oud). yet, only half of birthing people continue to use moud postpartum, increasing risk for overdose two-fold. this study will evaluate acceptability of a technology-enhanced behavioral intervention that aims to improve retention in and adherence to moud during the peripartum period. the intervention contains a brief behavioral intervention targeting malleable risk factors for treatment dropout, opioid cravings, and return to illicit opioid use: anxiety sensitivity and sleep deficiency. an adjunctive mobile application will supplement therapy sessions and contains a medication adherence feature involving daily (or multiple/day) notification reminder to take medication at a scheduled time and dose consistent with the participant's prescription.

Eligibility criteria:
inclusion criteria: * currently pregnant and less than 33 weeks gestational age, * history of oud within past 3 years, * confirmed prescription for sublingual buprenorphine products (i.e., suboxone, subutex, zubsolv) for the purpose of treating oud, * living in the united states, * between 18-45 years of age. exclusion criteria: * carrying multiples (i.e., twins, triplets, etc.); * high-risk pregnancies including the following conditions: hyperemesis defined as hospitalization for intractable nausea and vomiting, hypertensive disorders of pregnancy (e.g., gestational hypertension, preeclampsia), placenta previa, or vaginal bleeding in current pregnancy after the first trimester; * current psychotic symptoms and/or active suicidal intent; * experiencing cognitive or emotional impairment that precludes providing informed consent; * incarcerated/pending incarceration or institutionalized during the study period.

Keywords: anxiety mental health pregnancy psychiatry sleep disorders substance use women's health
molecular characterization of cutaneous tumors

Conditions: Squamous Cell Carcinoma; Basal Cell Carcinoma

Summary: the objective is to find genes which are responsible for the appearance of skin tumors (scc, bcc) and it will be the basis for prediction of the disease and response to the treatment

prospective, 1-arm, 500 participates above 18 age with skin tumor affliction scc and bcc type.

Eligibility criteria:
inclusion criteria: * patient that have scc and bcc tumors * above 18 years old exclusion criteria: * below 18 years old * pregnant women * children or person without judgment ability

Keywords: scc bcc dna rna hedge hog epidermal growth factor receptor
functional outcome assessment after (calcaneal) trauma surgey

Conditions: Fractures; Trauma; Surgery

Summary: to include patient after traumatic (calcaneal) fractures for this study. they can be included to analyze gait with the ofm foot model, a non invasis model. patient will be invited to the movement laboratory of the mumc. markers will be detached with dubble sided tape on anatomical points. after that gait will be recorded with infra-red camera's and an animation model will be formed. with this model further analysis can be made to range of motion between different segement of the foot. these results will be compared with patient with an arthrodesis, healthy subjects, futher questionnaires, physical examination and radiographic findings will be correlated.

all subjects are asked to come to the movement laboratory of maastricht university medical centre on one individual day. before gait analyses the following characteristics were measured; height, weight, bmi, knee and ankle width (measured between the two condyles of the knee and the measured between the two malleoli of the ankle) and leg length . all measurements are performed by researchers who was trained in the examination of the foot. at least one static trial was performed with all 42 markers, with the subjects in stance phase in an anatomic neutral position. after calibrating the markers and calculating the subject-specific joint axes in the static trial, 6 markers were removed, according to the ofm protocol. after that the subjects were asked to walk barefoot in normal speed after a number of practice trials. for this speed at least 8 proper recordings were made during walking. the healthy subjects were also asked to walk in slow speed and 8 proper recordings were made during this slow-speed walking. one whole step was considered complete from heel landing (initial contact) to toe-off. a force plate was used to determine the heel-strike and toe-off phase during walking. corrections in the axes of the knee and ankle were made if necessary and tiles were saved for further data output.

Eligibility criteria:
inclusion criteria: * patients with foot and ankle fractures exclusion criteria: * concomitant surgery for fractures of contra lateral leg/ankle or pre-existent abnormalities of the lower extremities, neurotrauma, spinal or neurological injury, pathologic fractures and people dependent in activities of daily living
vitamin d and type 2 diabetes risk in uk adults

Conditions: Overweight; Obesity

Summary: this study is exploring the association between vitamin d and type 2 diabetes risk in normal weight and overweight uk adults.

the aim of this study is to assess the link between vitamin d status and glucose homeostasis in a population of normal weight and overweight individuals (bmi\> 18.5 kg/m2).

Eligibility criteria:
inclusion criteria: * normal weight and overweight and obese adults (bmi\>= 18.5 kg/m2) with no restriction to ethnicity, occupation or socioeconomic status. * males and females * 18-50 years exclusion criteria: * patients diagnosed with diabetes type 2, myocardial infarction or coronary heart disease. * hba1c \> 6.4% * pregnancy * diagnosis of liver disease (including liver enzymes \> 3 times above normal values) * diagnosis of renal disease (creatinine of \> 150 mmol/l) * post-menopausal women

Keywords: vitamin d type 2 diabetes insulin resistance glucose
improving health outcomes of migraine patients who present to the emergency department

Conditions: Migraine

Summary: this is a pilot feasibility acceptability study to examine the impact of smartphone-based progressive muscle relaxation (pmr) on migraine quality of life, frequency, intensity, and disability. feasibility is measured by: a) proportion of patients who enrolled in the study/were recruited for the study, b) number of days pmr practiced/week as determined with the backend analytics in the relaxahead app, c) minutes/day spent doing pmr, d) reasons for non-adherence. acceptability is measured by: a) satisfaction using likert scale questions on relaxahead usability, content, and functionality b) willingness to repeat a similar treatment intervention in the future (definitely no/probably no/unsure/probably yes/ definitely yes) c) attrition. in addition, whether use of electronically based pmr introduced in the emergency department (ed) improves migraine quality of life (msqv2) and migraine related disability (midas) at 3 months post ed-discharge (or post enrollment date if recruited post ed discharge) compared to those who are not introduced to pmr will be assessed. all participants will be asked to track their headache frequency and intensity using our smartphone application (app) and will be asked to complete migraine quality of life assessments and migraine related disability at follow-up.

while explaining the study, potential participants will be assured that they will receive all of the medication for their acute headache that they would otherwise receive. once consented, participants will be randomized to pmr therapy or monitored usual care (muc). participants will be told that either group is being tested as an enhancement to the care they typically get in the ed for headache. (at the end, they will be informed which group they were in.) the study team will collect participants' health histories (biologic variables) and baseline data in redcap, download the app onto subjects' smartphones, and conduct the sessions.

Eligibility criteria:
inclusion criteria: * meets migraine criteria and has 4+ headache days a month exclusion criteria: * patients who have had cognitive behavioral therapy, biofeedback or other relaxation therapy in the past year * cognitive deficit or other physical problem with the potential to interfere with behavioral therapy * alcohol or other substance abuse as determined by self-report or prior documentation in the medical record * unable or unwilling to follow a treatment program that relies on written and audio recorded materials * not having a smartphone